{"disease":{"id":"metapneumovirus","name":"metapneumovirus"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06686654","title":"Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1530,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT06134648","title":"Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":646,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT06237296","title":"Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":558,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT03460171","title":"Clinical Features, Outcome and Prognosis of Human Metapneumovirus (hMPV) Lower Respiratory Tract Infections in Adult Inpatients","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06604767","title":"Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":390,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT06850051","title":"A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":270,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06984094","title":"First-in-human Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":192,"lead_sponsor_name":"Clover Biopharmaceuticals AUS Pty","has_results":false},{"nct_id":"NCT05743881","title":"A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":186,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT03392389","title":"Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT04144348","title":"Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT06546423","title":"Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT04933968","title":"Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":17,"lead_sponsor_name":"AlloVir","has_results":true},{"nct_id":"NCT04896853","title":"Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9,"lead_sponsor_name":"NextCell Pharma Ab","has_results":false},{"nct_id":"NCT04431050","title":"Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens","phase":"","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Imperial College London","has_results":true},{"nct_id":"NCT03502694","title":"Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false}],"total":15},"guidelines":[],"source":"Drug Landscape verified database"}